High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy

BMC Cancer

Table 2 Patients’ characteristics according to dichotomized distribution of OX40 positive immune cells in primary cancer biopsies in the overall cohort (cut-off = 36.5 cells; n = 47)^a

	OX40 high	OX40 low	p-value
	n = 14 (100%)	n = 33 (100%)
Age (median, range)	57 (41–73)	59 (34–77)	0.464
FIGO stage			0.795
II	0	1 (3.0)
IIIA	0	1 (3.0)
IIIB	2 (14.3)	3 (9.1)
IIIC	11 (78.6)	21 (63.6)
IV	1 (14.1)	7 (21.2)
Residual disease			0.243
None	7 (50.0)	9 (27.3)
< 2 cm	5 (35.7)	12 (36.4)
> 2 cm	2 (14.3)	11 (33.3)
Numbers of chemotherapy cycles			0.057
< 6	0	7 (21.2)
6 or more	14 (100.0)	25 (75.8)
CS^b	13 (93.0)	20 (60.6)	0.027
CR^b	1 (14.1)	13 (39.4)	0.027
6-month RFS % (95%CI)^c	0.71 (0.41–0.88)	0.45 (0.28–0.61)	0.461
3-year OS % (95%CI)^c	0.38 (0.10–0.67)	0.46 (0.26–0.64)	0.780

^apercentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
^bCS chemosensitive, CR chemoresistant
^cRFS recurrence-free survival, OS overall survival

ISSN: 1471-2407